Survodutide, also known by its developmental code BI 456906, is an investigational compound recognized for its potential role in weight management. It operates as a dual agonist, meaning it activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This dual action is a key aspect of its proposed mechanism for affecting metabolic processes. The compound is administered via injection and is currently undergoing clinical trials to assess its safety and efficacy for various conditions, particularly obesity and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). Its half-life in the body is approximately 170 hours, supporting less frequent dosing regimens. (Source: ClinicalTrials.gov, DrugBank)
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Frequently asked
Sources referenced
- ClinicalTrials.gov
- PubChem
- DrugBank
- Scientific literature reviews
- Peer-reviewed journal articles (e.g., New England Journal of Medicine, The Lancet)
- Scientific abstracts from professional conferences (e.g., EASL, ADA)
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the glp1 category or studied for the same goals.
